Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Add filters

Year range
Front Microbiol ; 13: 884034, 2022.
Article in English | MEDLINE | ID: covidwho-1847188


Since the outbreak of the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), public health worldwide has been greatly threatened. The development of an effective treatment for this infection is crucial and urgent but is hampered by the incomplete understanding of the viral infection mechanisms and the lack of specific antiviral agents. We previously reported that teicoplanin, a glycopeptide antibiotic that has been commonly used in the clinic to treat bacterial infection, significantly restrained the cell entry of Ebola virus, SARS-CoV, and MERS-CoV by specifically inhibiting the activity of cathepsin L (CTSL). Here, we found that the cleavage sites of CTSL on the spike proteins of SARS-CoV-2 were highly conserved among all the variants. The treatment with teicoplanin suppressed the proteolytic activity of CTSL on spike and prevented the cellular infection of different pseudotyped SARS-CoV-2 viruses. Teicoplanin potently prevented the entry of SARS-CoV-2 into the cellular cytoplasm with an IC50 of 2.038 µM for the Wuhan-Hu-1 reference strain and an IC50 of 2.116 µM for the SARS-CoV-2 (D614G) variant. The pre-treatment of teicoplanin also prevented SARS-CoV-2 infection in hACE2 mice. In summary, our data reveal that CTSL is required for both SARS-CoV-2 and SARS-CoV infection and demonstrate the therapeutic potential of teicoplanin for universal anti-CoVs intervention.

Disaster Med Public Health Prep ; : 1-7, 2021 May 18.
Article in English | MEDLINE | ID: covidwho-1232052


OBJECTIVE: The aim of this study was to present the clinical characteristics and dynamic changes in laboratory parameters of the coronavirus disease 2019 (COVID-19) in Guangzhou, and explore the probable early warning indicators of disease progression. METHOD: We enrolled all the patients diagnosed with COVID-19 in the Guangzhou No. 8 People's Hospital. The patients' demographic and epidemiologic data were collected, including chief complaints, lab results, and imaging examination findings. RESULTS: The characteristics of the patients in Guangzhou are different from those in Wuhan. The patients were younger in age, predominately female, and their condition was not commonly combined with other diseases. A total of 75% of patients suffered fever on admission, followed by cough occurring in 62% patients. Comparing the mild/normal and severe/critical patients, being male, of older age, combined with hypertension, abnormal blood routine test results, raised creatine kinase, glutamic oxaloacetic transaminase, lactate dehydrogenase, C-reactive protein, procalcitonin, D-dimer, fibrinogen, activated partial thromboplastin time, and positive proteinuria were early warning indicators of severe disease. CONCLUSION: The patients outside epidemic areas showed different characteristics from those in Wuhan. The abnormal laboratory parameters were markedly changed 4 weeks after admission, and also were different between the mild and severe patients. More evidence is needed to confirm highly specific and sensitive potential early warning indicators of severe disease.

SciFinder; 2020.
Preprint | SciFinder | ID: ppcovidwho-2058


Objective: To master the situation of antiviral treatment for Corona Virus Disease 2019(COVID-19) and explore the key points of pharmaceutical care, thereby provide a reference for promoting clin. rational administration of drug and pharmaceutical care for COVID-19 patients. Methods:Retrospective anal. method was adopted to analyze the antiviral treatment, clin. efficacy and safety for COVID-19 outpatients from Jan. 26, 2020 to Mar. 12, 2020 in Guangzhou Eighth People's Hospital, a designated hospital for COVID-19, and the key points of pharmaceutical care was investigated. Results: A total of 241 patients received antiviral treatment, accounting for 80.60% of COVID-19 patients discharged in the same period, the rate of cure was 94.19%. The initial treatment was single drug therapy of lopinavir/ritonavir, arbidol and chloroquine phosphate, 29.88% of the patients needed to adjust the treatment plan. During the study period, the proportion of treatment with lopinavir/ritonavir decreased gradually and the proportion of arbidol and chloroquine phosphate increased successively. 71 Patients (29.46%) had antiviral drug-related ADRs. Conclusion: The clin. treatment of COVID-19 was mainly antiviral monotherapy. The commonly used drugs were lopinavir/ritonavir, arbidol and chloroquine phosphate, the latter two drugs were gradually optimized in clin. treatment. It was necessary to monitor the gastrointestinal reaction, ECG, liver and kidney function during the treatment, and avoid adverse DDIs. Meanwhile, the individual treatment and pharmaceutical care for severe and critical patients should be strengthened.